Redx Pharma plc MHRA approval of Clinical Trial Application (0502J)
June 23 2017 - 8:38AM
UK Regulatory
TIDMREDX
RNS Number : 0502J
Redx Pharma plc
23 June 2017
23 June 2017
AIM: REDX
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY
THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER
THE MARKET ABUSE REGULATION. UPON THE PUBLICATION OF THE
ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION
IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.
REDX PHARMA PLC (in administration)
("Redx" or "the Company")
Redx announces MHRA approval of its Clinical Trial Application
for Porcupine Inhibitor RXC004
Redx (AIM: REDX), the drug discovery and development company
focused on cancer and immunology, announces that it has received
approval from the UK Medicines and Healthcare Products Regulatory
Agency (MHRA) and the Ethics Review Committee for its Clinical
Trial Application (CTA) for the Porcupine inhibitor RXC004. The
approval provides permission for Redx to initiate a Phase IB/ Phase
IIA study of RXC004 in patients suffering from gastric, biliary and
pancreatic cancer.
RXC004 is an oral, small molecule Porcupine inhibitor in
development as a monotherapy for difficult to treat cancers. In
addition, the Company would look to explore the potential of RXC004
in combination with a PD-1 checkpoint inhibitor.
Iain Ross, non-executive Chairman, commented, "Receiving
regulatory approval to advance our first program into clinic is a
major step forward in Redx's development. We believe that RXC004
has great potential to treat some very challenging cancers that
currently have very poor prognosis."
For further information, please contact:
Redx Pharma Plc (in administration)
Contact for the Joint Administrators:
James Rossiter (Morgan Rossiter) + 44 203 195 3240
Cantor Fitzgerald Europe (Nomad & Broker) +44 207 894 7000
Phil Davies/ Michael Reynolds
WG Partners (Joint Broker) +44 203 705 9317
Claes Spång/ Chris Lee/ David Wilson
About RXC004
Redx's Porcupine inhibitor RXC004 exhibits potent and selective
inhibition of the Wnt pathway in in vitro and in vivo models of Wnt
dependant cancer. Preliminary results indicate that RXC004 may also
enhance the efficacy of checkpoint inhibitors, such as anti-PD-1
antibodies.
About Redx Pharma Plc (in administration)
Company website: Redxpharma.com
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, immunology and infection, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a broad portfolio of proprietary drug programs.
Jason Baker and Miles Needham have been appointed as joint
administrators of Redx Pharma plc (in administration). The
Company's affairs, business and property are being managed by the
joint administrators.
This information is provided by RNS
The company news service from the London Stock Exchange
END
REAPGUAWQUPMGWW
(END) Dow Jones Newswires
June 23, 2017 09:38 ET (13:38 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024